logo

Biotech Daily Dose

Share

pharmaclr-aug17.jpg As another week comes to a close, it's time to take a quick look at some of the news that made headlines in the pharma sector, and look ahead at the events to keep an ear out for in the coming week.

pharma-daily-081518.jpg Today's Daily Dose brings you news about Accuray's financial results; stock offerings of AVEO and Pain Therapeutics; Evoke Pharma's upcoming regulatory catalyst in April and FDA approval for expanded indication for Eisai/Merck's Lenvatinib.

daily-pharma-081418.jpg Today's Daily Dose brings you news about Actinium's immediate catalyst; CEL-SCI Corp' progress in phase III Multikine study; PetIQ's upbeat outlook; Motif Bio's regulatory catalyst and ViewRay's stock offering.

pharma-daily081318.jpg Today's Daily Dose brings you news about Atossa's near-term catalyst; Acer's progress in vascular Ehlers-Danlos syndrome trial; Eiger's phase II PREVENT study, and Mustang Bio's deal with St. Jude Children's Research Hospital for bubble boy gene therapy.

pharma-weekly-081018.jpg The week that passed by was an action-packed one for the pharma sector, with a number of "firsts" happening on the regulatory front. Now, here are some of the pharma/biotech stocks and upcoming events to keep an ear out for in the coming week.

pharma-daily-080918.jpg Today's Daily Dose brings you news about stock offerings of Restoration Robotics and NeoGenomics; Spero's clinical trial catalyst to watch in Q3; update on Iterum's SURE study; Viking and Puma's anticipated milestones.

pharma-daily-080818.jpg Today's Daily Dose brings you news about FDA panel vote on Paratek Pharma's antibiotic Omadacycline; Rite Aid calling off merger with privately held Albertsons Companies; United Therapeutics' settlement of patent litigation with Watson Laboratories Inc., relating to Tyvaso; Otonomy's anticipated events, and second quarter financial results of Nektar and Novavax.

pharma-daily-080718.jpg Today's Daily Dose brings you news about FDA panel recommendation of Insmed's inhaled antibiotic; Bellerophon's disappointing INOpulse study results; mixed study results of Spark's investigational gene therapy SPK-8011 for hemophilia A, and FDA approval of Vertex Pharma's cystic fibrosis drug.

pharma-aug-7.jpg Today's Daily Dose brings you news about ACADIA's North American License Agreement with Neuren Pharma; upcoming milestones of Akcea; product development agreement between Antares and Pfizer; CryoLife's Q2 results and upbeat outlook; partial clinical hold on Gemphire's Gemcabene, and InspireMD's and Vericel's Q2 financial results.

pharma-august-080318.jpg We are in the middle of second-quarter earnings season, with many of the pharma giants having reported better-than-expected results and issuing an upbeat outlook.

Today's Daily Dose brings you news about BioCryst Pharma's stock offering; AxoGen and Blueprint Medicines' strong Q2 financial results; positive results of RXi Pharmaceuticals' phase I/II trial with RXI-109 for retinal scarring and reverse stock split of Synthetic Biologics.

pharma-daily-073118.jpg Today's Daily Dose brings you news about Apellis Pharma's pipeline progress; licensing agreement between Knight Therapeutics and TherapeuticsMD; anticipated milestones of Progenics Pharma, and discontinuation of Shire's phase II NASH trial.

pharma-daily-073018.jpg Today's Daily Dose brings you news about second quarter financial results of GenMark, Illumina and Tandem; anticipated milestones of Lexicon Pharma; Nektar's regulatory catalyst and FDA approval of Progenics' radioactive therapeutic Azedra, among others.

chmp-july30.jpg The European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, issued its opinion related to approval of the following drug candidates on Friday. Once a CHMP opinion is announced, it takes 67 days for the European Commission to announce its decision.

pharma-july-072018.jpg As another week comes to a close, let's take a look back at some of the stories that made headlines in the pharma space, and look ahead to what's in store in the coming week.

Follow RTT